How does triple-negative status influence your management of ET?

This is a fantastic question! First, I would ensure that the patient has triple negative ET (or pre-fibrotic PMF) and not a secondary cause for thrombocytosis. This requires a bone marrow biopsy and a careful examination with hematopathology to ensure there are morphologic features consistent with an MPN.

In terms of aspirin, the benefit in low-risk patients appears largely confined to JAK2 mutated patients who are at a higher risk of thrombosis (Alvarez-Larrán et al., PMID 20508163). Therefore, ...